The Halifax Group Promotes Three to Partner

Expands Senior Management Team

Washington, D.C. —April 11, 2016 — The Halifax Group, a leading private equity firm that partners with management to invest in entrepreneurial companies, announced today that it has named three longtime employees as partners and members of the firm’s investment committee, effective immediately. All three were formerly principals at the firm.

Scott Van Duinen has been with Halifax since 2004 and is responsible for the origination, evaluation, execution and monitoring of numerous investments. Scott has also served on numerous portfolio boards and is currently Chairman of K2 Industrial Services and U.S. Environmental Services.

Scott Plumridge joined Halifax in 2005 and also assists in sourcing, evaluation, execution and monitoring of portfolio investments and has served on numerous Halifax boards. Scott is on the boards of XLA, Pirtek Europe and Envision Pharma Group.

Chris Cathcart joined Halifax in 2007 and leads Halifax’s business development program. He has been responsible for the development and continued evolution of the firm’s proprietary origination program, deal underwriting and tracking system and oversight of investor relations.

All three will also join the Investment Committee of Halifax, effective immediately.

David Dupree, Senior Partner and co-founder, said, “We are delighted to recognize the contributions Scott, Scott and Chris have made to the firm and its growth over the last decade. In addition, their move to partnership roles ensures the continuity of management of Halifax in the years to come. Their efforts have helped Halifax ensure robust deal flow, manage our portfolio companies effectively, and deliver exceptional value to our investors.”

Halifax is investing out of Halifax Capital Partners III, L.P. (HCP III), which closed in 2012. The firm’s current portfolio companies include Envision Pharma Group, Golden State Overnight, Pirtek Europe, and U. S. Environmental Services. Caring Brands International, also a HCP III investment, was recently sold.